Systemic Therapy for Stage IV Non-small Cell Lung Cancer With Driver Alterations Source: American Society of Clinical Oncology; Medically Reviewed by Professor Sanjay Popat May 06, 2026

Systemic Therapy for Stage IV Non-small Cell Lung Cancer With Driver Alterations Source: American Society of Clinical Oncology; Medically Reviewed by Professor Sanjay Popat May 06, 2026 https://reference.medscape.com/cc2/p10/asco-guideline-stage-iv-nsclc-driver-2025a1000mx0?ecd=WNL_drugguide_260517_MSCPREF_onc_etid8346256&uac=148436CN&impID=8346256 Latest Guidance Updates February 2026: new and updated recommendations on first- and second-line treatment for NSCLC with EGFR, ROS1, BRAF, MET, RET, and NTRK mutations. New and updated recommendations on second-line or subsequent therapies for NSCLC with ALK and HER2 mutations